Critical Contrast: Definium Therapeutics (NASDAQ:DFTX) vs. Tetra Bio-Pharma (OTCMKTS:TBPMF)

Definium Therapeutics (NASDAQ:DFTX) and Tetra Bio-Pharma (OTCMKTS:TBPMF) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

27.9% of Definium Therapeutics shares are held by institutional investors. 2.3% of Definium Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Definium Therapeutics and Tetra Bio-Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1	0	8	3	3.08
Tetra Bio-Pharma	0	0	0	0	0.00

Definium Therapeutics presently has a consensus target price of $35.22, indicating a potential upside of 104.31%. Given Definium Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Definium Therapeutics is more favorable than Tetra Bio-Pharma.

Earnings & Valuation

This table compares Definium Therapeutics and Tetra Bio-Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$108.68 million	($2.04)	-8.45
Tetra Bio-Pharma	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Definium Therapeutics and Tetra Bio-Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-86.18%	-62.29%
Tetra Bio-Pharma	N/A	N/A	N/A

Summary

Definium Therapeutics beats Tetra Bio-Pharma on 6 of the 8 factors compared between the two stocks.

About Definium Therapeutics

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

About Tetra Bio-Pharma

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.